Creative Planning
APTO

Creative Planning’s Aptose Biosciences, Inc. APTO Stock Holding History

Creative Planning’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-167
Closed -$156K – 2137
2019
Q3 		$156K Buy
+167
New +$190K ﹤0.01% 1659
2017
Q2 		– Sell
-2
Closed -$1K – 4900
2017
Q1 		$1K Buy
+2
New +$1.02K ﹤0.01% 4532

Other funds holding APTO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return

Creative Planning's APTO Position: Q4 2019 in Review

Creative Planning sold out of Aptose Biosciences, Inc. (APTO) in Q4 2019, closing a stake of 167 shares — an estimated $156K sold.

Creative Planning first reported a position in APTO in Q1 2017 and held it in 2 quarters. The position peaked at $156K in Q3 2019. 56 funds tracked by Wall St. Rank hold APTO as of Q4 2019.

  • Creative Planning reported no remaining Aptose Biosciences, Inc. position as of Q4 2019 after selling out during the quarter.
  • Creative Planning sold 167 Aptose Biosciences, Inc. shares in Q4 2019, an estimated $156K.
  • Creative Planning first reported a position in Aptose Biosciences, Inc. in Q1 2017 and held it in 2 quarters.
  • Creative Planning's Aptose Biosciences, Inc. position peaked at $156K in Q3 2019.
  • 56 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2019.

Based on Creative Planning's 13F filing for Q4 2019, filed 30 Jan 2020.